Mankind Pharmaceuticals, a company known for its brands Manforce and Prega News, will launch its IPO soon. We have a full review of Mankind Pharmaceuticals, including what the firm does, the promoters, the company’s financials, and how the company expects to use the money from the public offering. Understanding these facts could help you decide if you should subscribe or pass.
About Mankind Pharmaceuticals
Mankind Pharmaceuticals Ltd is a significant player in India’s pharmaceutical industry, coming in fourth for domestic sales and second for sales volume during the 2022 fiscal year. They research, produce, and sell a range of pharmaceuticals and consumer healthcare goods to meet acute and long-term requirements. With a strong emphasis on the local market, the bulk of their income – 97.60% – came from activities in India during the fiscal year 2022, making them one of the most successful firms in this respect among their peers.
Mankind Pharmaceuticals IPO Details
Mankind Pharmaceuticals, the biggest pharmaceutical company in India, is planning to launch an initial public offering (IPO) with a 100% offer for sale or book-built issue. The table below contains all the details about the Mankind Pharmaceuticals IPO.
|IPO Status||Draft Offer Documents filed with SEBI|
|IPO Date||January 2023|
|IPO Size||Rs. 5500cr|
|Lot Size||Not disclosed yet|
|IPO Price Band||Not disclosed yet|
|Issue Type||Book Building|
|IPO Listing at||BSE & NSE|
|Face Value||Rs. 1/Equity Share|
|Listing Date||Not disclosed yet|
|Offer for Sale||40,058,844 Equity Shares|
Category-wise Percentage of shares offered.
What does Mankind Pharmaceuticals do?
Research and development are one of Mankind Pharmaceuticals’ primary business sectors. This sector is in charge of researching and developing new pharmaceutical products and enhancing those already on the market. This is an essential business component since it enables them to stay one step ahead of the competition and offer cutting-edge therapies.
Manufacturing is another crucial aspect of business for Mankind Pharmaceuticals. The company’s medicinal items are produced in this department. The whole manufacturing process is covered, from raw materials to completed goods. Production of both generic and exclusive items is included in this.
Sales and marketing make up Mankind Pharmaceuticals’ third line of operation. The items of the business are promoted and sold in this region. This covers sales, public relations, promotions, and advertising. To ensure that the products are efficiently promoted to the appropriate target market, the marketing and sales team collaborates closely with the research and development team.
Furthermore, a distribution network is also present for Mankind Pharmaceuticals. The company’s products are delivered to clients via this department. Hospitals, merchants, and wholesalers are included in this. T dIn addition, this division manages inventory levels, logistics, and shipping for the company’s goods.
Mankind Primary Products
The business offers a variety of condoms under the Manforce brand. Manforce placed first in the male condom category for domestic sales in the Financial Year 2022, with a market share of around 30.2%.
Prega News is a simple-to-use home pregnancy screening tool that uses urine samples to identify pregnancies. Prega News rated first in the pregnancy test kit category for Domestic Sales in the Financial Year 2022, with a market share of around 80.1% as of March 31, 2022.
Ayurvedic oral antacid powder with many flavors, called Gas-O-Fast, is intended to treat acidity, heartburn, and indigestion symptoms. Gas-O-Fast placed fifth in the molecular category in domestic sales for the Financial Year 2022, with a market share of almost 4.0%.
Unwanted-72 is an emergency contraceptive pill to prevent unwanted pregnancies due to unprotected intercourse or contraceptive failure. To be effective, the medication must be taken within 72 hours following sexual activity.
Unwanted-21 Days, a birth control tablet, is part of this contraceptive line. As a result, unwanted-72 led the emergency contraception market in domestic sales for the Financial Year 2022, with a market share of almost 59.2%.
AcneStar is a clindamycin, nicotinamide-containing anti-inflammatory and anti-bacterial gel used to treat acne. With a market share of around 13.2% in the category of acne preparations for the Financial Year 2022, AcneStar placed second in terms of domestic sales.
The prescription market includes products for high blood pressure (Amlokind), antibiotics (Moxikind-CV), vitamins (Nurokind), and other products.
Financial Health – Mankind Pharmaceuticals IPO
Mankind Pharma Ltd is a domestic-focused pharmaceutical company with significant growth potential. The company’s market share in the Indian pharmaceutical market (IPM) increased by 0.4% between 2020 and 2022, from 4.0% to 4.4%, making it the fastest-growing among the top 10 corporates in the IPM by Domestic Sales.
The Government of India has implemented Production Linked Incentive (PLI) schemes to promote domestic manufacturing of critical key starting materials, drug intermediates, and APIs, which will help to reduce India’s dependence on imports and support the growth of domestic-focused businesses like Mankind Pharma.
Domestic Sales for Mankind Pharma grew at a CAGR of 16% between 2020 and 2022, outperforming the overall IPM growth in domestic sales by 1.5 times. As a result, they aim to continue increasing their presence in the IPM and have a market presence of approximately 64% of the IPM in terms of Domestic Sales for 2022.
Additionally, Mankind Pharma has established several consumer healthcare brands in various categories, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations.
Mankind IPO is at threat of the following:
- Quality control or manufacturing issues may harm the company’s reputation, lead to regulatory action, and result in litigation or other liabilities.
- The pharmaceutical and consumer healthcare industries are highly competitive. Therefore, if the company cannot compete effectively, it could lose market share and see a decline in revenues and profits, negatively impacting its business.
- Damage to the company’s brands, product image, or reputation could negatively impact market recognition and trust in its products.
- Duplicate products in the market could damage the reputation of the brand.
- Disruptions, slowdowns, or shutdowns in the manufacturing or R&D operations could harm the company’s business, financial condition, cash flows, and results of operations.
Should You Subscribe to Mankind Pharmaceuticals IPO or Not?
IPO investments are subject to market risk research the company and understand your risk tolerance before investing.
In conclusion, Mankind Pharma Limited is a domestic-focused pharmaceutical company with significant growth potential in the Indian Pharmaceutical market as of 2022. The company has several consumer healthcare brands in different categories and is planning to go public by issuing shares to the public through an Initial Public Offering (IPO).
However, like any other investment, there are risks involved, such as intense competition in the pharmaceutical industry, issues with quality control, potential damage to the company’s reputation and brands, and disruptions in manufacturing or R&D operations. It is essential to conduct thorough research and consider these risks before investing in an IPO.
Disclaimer: The numbers mentioned in this article are for information purposes only. He/she should not consider this a buy/sell/hold recommendation from Research & Ranking. The company shall not be liable for any losses that occur.
Has Mankind Pharma been publicly traded?
Mankind Pharma is now in the process of being listed on both the NSE and the BSE.
When is Mankind Pharma IPO going to happen?
The IPO date has yet to be confirmed, but it is expected to happen in January 2023.
What is the Mankind IPO’s minimum order quantity?
The minimum lot size for the forthcoming IPO is not disclosed yet.
Read more: About Research and Ranking